查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1500362

學名藥市場：按類型、給藥途徑、適應症、分佈分類 - 全球預測 2024-2030

Generic Drugs Market by Type (Simple Generic, Specialty Generic), Route of Administration (Inhalable, Injectable, Oral), Indication, Distribution - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年學名藥市場規模為2,991.6億美元，預計2024年將達3,162.7億美元，複合年成長率為5.91%，2030年將達4,474.5億美元。

學名藥的設計與原廠藥的劑型、規格、給藥途徑、品質、性能特徵和預期用途相同，並在原廠藥的專利保護期滿後以較低的價格出售。這些產品為世界各地的消費者和醫療保健系統提供了重要的成本節約優勢。學名藥在廣泛的治療領域有廣泛的應用，包括心血管、糖尿病、神經、腫瘤和感染疾病。學名藥的最終用戶主要是醫院、診所和藥房等醫療保健提供者，透過店面銷售）直接銷售給消費者。與品牌產品相比，學名藥的可負擔性是市場成長的主要動力。政府透過有利的法規和政策支持學名藥的使用，以降低醫療成本，正在推動學名藥市場的成長。由於世界各地慢性病的增加，對學名藥的需求正在擴大。 ：對學名藥品質和功效的擔憂以及各國監管政策的嚴格差異正在阻礙市場成長。開拓新型藥物輸送系統的新興市場以提高療效和患者依從性預計將創造市場成長機會。由於研究重點是降低製造成本並證明與原廠生技藥品的相似性，生物相似藥產品的擴張預計將推動市場成長。

主要市場統計
基準年[2023] 2991.6億美元
預測年份 [2024] 3162.7億美元
預測年份 [2030] 4474.5億美元
複合年成長率（%） 5.91%

區域洞察

美洲是學名藥的新興市場，受到對負擔得起的醫療保健解決方案的高需求和政府政策的大力支持的推動。最近，學名藥用戶費用修正案 (GDUFA) 等舉措旨在加快學名藥的核准流程，加強市場。消費者對學名藥有很強的信任度，每年都會開出大量的學名藥處方箋。在旨在加速高品質學名藥開發和核准的政府改革的推動下，亞太地區的學名藥市場正在經歷快速成長。該地區專注於創新，透過投資研發和簡化監管流程來加強當地產業。在歐盟，法律規範平衡了創新和競爭的需要，同時鼓勵學名藥的開發和分銷。歐盟範圍內的各種舉措支持學名藥進入市場，並創造有利於消費者的競爭環境。隨著世界各國政府實施促進學名藥使用的政策，中東和非洲的學名藥市場正在不斷擴大。這是提高該地區醫療保健的可負擔性和可近性的更廣泛策略的一部分。

FPNV定位矩陣

FPNV定位矩陣對於評估供應商在學名藥市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對學名藥市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外，該分析還提供了對該行業競爭力的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在學名藥市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的增加和對具有成本效益的藥物的需求
      • 政府對學名藥的優惠支持
      • 透過線上藥局增加學名藥的可得性
    • 抑制因素
      • 病人和醫生對品牌藥物的偏好
    • 機會
      • 與學名藥開發相關的持續研發活動
      • 專利到期並增加製造學名藥的戰略長期合作夥伴關係
    • 任務
      • 對品質和製造差異的擔憂
  • 市場區隔分析
    • 類型：擴大應用於複雜和慢性疾病的治療
    • 分銷：由於便利性、可近性和具競爭力的價格，網路藥局越來越受青睞。
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章學名藥市場：按類型

  • 簡單非專利
  • 特殊非專利

第7章學名藥市場：依管理途徑

  • 吸入式
  • 可注射的
  • 口服

第8章學名藥市場（按適應症）

  • 癌症
  • 心血管疾病
  • 中樞神經系統疾病
  • 糖尿病
  • 消化系統疾病
  • 荷爾蒙與相關疾病
  • 感染疾病
  • 呼吸系統疾病

第9章學名藥市場經銷商

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章美洲學名藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區學名藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲學名藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • BDR Pharma 推出治療真菌感染疾病的學名藥，成本僅為三分之一
    • Amneal 推出已獲批准的非專利Xyrem（奧昔巴特鈉），並獲得 FDA核准其五種複合非專利
    • Mediplus Health Service 推出自有品牌學名藥
  • 戰略分析和建議

第14章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-F6513A06BE93

[199 Pages Report] The Generic Drugs Market size was estimated at USD 299.16 billion in 2023 and expected to reach USD 316.27 billion in 2024, at a CAGR 5.91% to reach USD 447.45 billion by 2030.

The generic drugs are designed to be identical in dosage form, strength, route of administration, quality, performance characteristics, and intended use to their branded counterparts and are sold at a lower price once the patent protection of the original brand-name drug has expired. These products offer a vital cost-saving advantage to consumers and healthcare systems worldwide. Generic drugs find their application across a broad spectrum of therapeutic areas, including cardiovascular, diabetes, neurology, oncology, and infectious diseases, among others. The end-users of generic drugs are primarily healthcare providers such as hospitals, clinics, and pharmacies, and they are sold directly to consumers through over-the-counter (OTC) sales. The affordability of generic drugs compared to their branded counterparts remains a primary driver for market growth. Growing government support for the use of generic drugs through favorable regulations and policies to reduce healthcare costs is driving the growth of the generic drug market. The rising incidences of chronic conditions globally are expanding the need for generic drugs. : Concerns over the quality and efficacy of generic drugs and stringent and varying regulatory policies across different countries hamper the market growth. The growing development of novel drug delivery systems to enhance efficacy and patient compliance is expected to create opportunities for market growth. Expanding into biosimilar products, with research focused on reducing production costs and proving similarity to originator biologics, is anticipated to fuel market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 299.16 billion
Estimated Year [2024] USD 316.27 billion
Forecast Year [2030] USD 447.45 billion
CAGR (%) 5.91%

Regional Insights

The Americas stands as the highly developing market for generic drugs, driven by a high demand for affordable healthcare solutions and strong support from governmental policies. Recently, initiatives such as the Generic Drug User Fee Amendments (GDUFA) aim to speed up the approval process for generic drugs, bolstering the market. Consumer trust in generics is high, with a large percentage of prescriptions filled with generic drugs annually. Asia-Pacific's generic drug market is experiencing rapid growth, fueled by governmental reforms aimed at encouraging the development and approval of high-quality generics. The region is focusing on innovation with investments in R&D and streamlining regulatory processes to bolster the local industry. In the EU, the regulatory framework encourages the development and circulation of generic drugs, balancing the need for innovation and competition. Various EU-wide initiatives support market access for generics, fostering a competitive environment that benefits consumers. The market for generic drugs in the Middle East & Africa is growing, with governments implementing policies to promote the use of generics. This is part of a broader strategy to enhance healthcare affordability and accessibility in the region.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Generic Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising prevalence of chronic diseases and the need for cost-effective medications
      • Favorable government support for generic drugs
      • Growing availability of generic drugs through online pharmacies
    • Market Restraints
      • Preference for branded drugs by patients and physicians
    • Market Opportunities
      • Ongoing R&D activities associated with the development of generic drugs
      • Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
    • Market Challenges
      • Concerns associated with quality and manufacturing variability
  • Market Segmentation Analysis
    • Type: Expanding applications of for treating complex and chronic conditions
    • Distribution: Emerging preference for online pharmacies for convenience, accessibility, and competitive pricing
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Generic Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Generic Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

BDR Pharma launches generic drug for fungal infections at 1/3rd the cost

BDR Pharmaceutical introduced Zisavel capsules, a generic azole antifungal treatment aimed at addressing invasive aspergillosis and mucormycosis fungal infections at a significantly reduced cost. Zisavel is positioned as a cost-effective alternative, costing only a third of the price of current treatments. BDR Pharmaceuticals' initiative seeks to enhance the accessibility of essential medication, particularly isavuconazole, making it as affordable as other new-generation antifungal agents such as voriconazole and posaconazole. [Published On: 2023-09-29]

Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics

Amneal Pharmaceuticals, Inc. announced the U.S. introduction of its authorized generic version of Xyrem (Sodium Oxybate) oral solution, a central nervous system depressant aiding patients aged seven and above in managing cataplexy and excessive daytime sleepiness associated with narcolepsy. Alongside this significant release, Amneal shared news of receiving U.S. FDA approvals for five complex generics, including three injections, highlighting dexmedetomidine injection, acknowledged for addressing a current FDA shortage. [Published On: 2023-07-03]

Mediplus Health Services launches own brand of generic medicines

Mediplus Health Services expanded into the generic drug segment by introducing its proprietary line of generic medications, now accessible throughout its extensive 4,200-store network. This ambitious venture is supported by collaborations with renowned Contract Drug Manufacturing Organisations (CDMOs), including Akums India and Windlas Biotech, targeting the production of 706 different generic drugs. [Published On: 2023-02-09]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Generic Drugs Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Amneal Pharmaceuticals Inc, Aspen Holdings, Aurobindo Pharma Limited, Baxter International Inc., Cipla Ltd, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International plc., Fresenius SE & Co. KGaA., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC., Johnson & Johnson Services, Inc., Lupin Limited, Mylan N.V. by Viatris Inc., Pfizer Inc., Sandoz International GmbH by Novartis Group, Sanofi S.A., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Zydus Lifesciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Simple Generic
    • Specialty Generic
  • Route of Administration
    • Inhalable
    • Injectable
    • Oral
  • Indication
    • Cancer
    • Cardiovascular Diseases
    • Central Nervous System Disorders
    • Diabetes
    • Gastrointestinal Diseases
    • Hormones & Related Diseases
    • Infectious Diseases
    • Respiratory Diseases
  • Distribution
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and the need for cost-effective medications
      • 5.1.1.2. Favorable government support for generic drugs
      • 5.1.1.3. Growing availability of generic drugs through online pharmacies
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with the development of generic drugs
      • 5.1.3.2. Increasing patent expirations and strategic long-term partnerships to manufacture generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Expanding applications of for treating complex and chronic conditions
    • 5.2.2. Distribution: Emerging preference for online pharmacies for convenience, accessibility, and competitive pricing
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Generic Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Simple Generic
  • 6.3. Specialty Generic

7. Generic Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalable
  • 7.3. Injectable
  • 7.4. Oral

8. Generic Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Diseases
  • 8.4. Central Nervous System Disorders
  • 8.5. Diabetes
  • 8.6. Gastrointestinal Diseases
  • 8.7. Hormones & Related Diseases
  • 8.8. Infectious Diseases
  • 8.9. Respiratory Diseases

9. Generic Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Generic Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Generic Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Generic Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. BDR Pharma launches generic drug for fungal infections at 1/3rd the cost
    • 13.3.2. Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Generics
    • 13.3.3. Mediplus Health Services launches own brand of generic medicines
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. GENERIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENERIC DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERIC DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY SIMPLE GENERIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY SIMPLE GENERIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY SPECIALTY GENERIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC DRUGS MARKET SIZE, BY SPECIALTY GENERIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC DRUGS MARKET SIZE, BY INHALABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC DRUGS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC DRUGS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC DRUGS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC DRUGS MARKET SIZE, BY GASTROINTESTINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC DRUGS MARKET SIZE, BY HORMONES & RELATED DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC DRUGS MARKET SIZE, BY HORMONES & RELATED DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL GENERIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL GENERIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. CANADA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 76. CANADA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. MEXICO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 84. MEXICO GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 85. MEXICO GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. MEXICO GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 93. UNITED STATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 94. UNITED STATES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 95. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 96. UNITED STATES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES GENERIC DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 112. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 116. AUSTRALIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. CHINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 120. CHINA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 121. CHINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 122. CHINA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 123. CHINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 124. CHINA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 128. INDIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 129. INDIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. INDIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. INDIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 132. INDIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. INDONESIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 136. INDONESIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 137. INDONESIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 138. INDONESIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 139. INDONESIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 140. INDONESIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. JAPAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 144. JAPAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 145. JAPAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 146. JAPAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 147. JAPAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 148. JAPAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. MALAYSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 152. MALAYSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 153. MALAYSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 154. MALAYSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 155. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 156. MALAYSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 160. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 164. PHILIPPINES GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SINGAPORE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 168. SINGAPORE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 169. SINGAPORE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. SINGAPORE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 172. SINGAPORE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 176. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 178. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 180. SOUTH KOREA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. TAIWAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 184. TAIWAN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 185. TAIWAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. TAIWAN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. TAIWAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 188. TAIWAN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. THAILAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 192. THAILAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 193. THAILAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. THAILAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. THAILAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 196. THAILAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. VIETNAM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 200. VIETNAM GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 201. VIETNAM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 202. VIETNAM GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 203. VIETNAM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 204. VIETNAM GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. DENMARK GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 218. DENMARK GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 219. DENMARK GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 220. DENMARK GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 221. DENMARK GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 222. DENMARK GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. EGYPT GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 226. EGYPT GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 227. EGYPT GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 228. EGYPT GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 229. EGYPT GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 230. EGYPT GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FINLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 234. FINLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 235. FINLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. FINLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. FINLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 238. FINLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. FRANCE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 242. FRANCE GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 243. FRANCE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 244. FRANCE GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 245. FRANCE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 246. FRANCE GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. GERMANY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 250. GERMANY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 251. GERMANY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 252. GERMANY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 253. GERMANY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 254. GERMANY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ISRAEL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 258. ISRAEL GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 259. ISRAEL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. ISRAEL GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. ISRAEL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 262. ISRAEL GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. ITALY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 266. ITALY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 267. ITALY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 268. ITALY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 269. ITALY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 270. ITALY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 274. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 276. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 278. NETHERLANDS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NIGERIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 282. NIGERIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 283. NIGERIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 284. NIGERIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 285. NIGERIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 286. NIGERIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. NORWAY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 290. NORWAY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 291. NORWAY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 292. NORWAY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 293. NORWAY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 294. NORWAY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. POLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 298. POLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 299. POLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 300. POLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 301. POLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 302. POLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. QATAR GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 306. QATAR GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 307. QATAR GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 308. QATAR GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 309. QATAR GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 310. QATAR GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. RUSSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 314. RUSSIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 315. RUSSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 316. RUSSIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 317. RUSSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 318. RUSSIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 322. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 324. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 326. SAUDI ARABIA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 330. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 332. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 334. SOUTH AFRICA GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 337. SPAIN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 338. SPAIN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 339. SPAIN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 340. SPAIN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 341. SPAIN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 342. SPAIN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 345. SWEDEN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 346. SWEDEN GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 347. SWEDEN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 348. SWEDEN GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 349. SWEDEN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 350. SWEDEN GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 354. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 355. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 356. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 357. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 358. SWITZERLAND GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 359. TURKEY GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 360. TURKEY GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 361. TURKEY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 362. TURKEY GENERIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 363. TURKEY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 364. TURKEY GENERIC DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 365. TURKEY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 366. TURKEY GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 367. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 368. UNITED ARAB EMIRATES GENERIC DRUGS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 369. UNITED ARAB EMIRATES GENERIC DR